Vancouver, British Columbia – May 4, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB), announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO International, taking place June 15-18 at the Pennsylvania Convention Center, Philadelphia PA.
BIO International is the industry’s premier conference and partnering opportunity. It is the largest global event for the biotechnology industry and attracts the biggest names in biotech and pharma. With more than 15,000 expected to attend, BIO International offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.
“Bio is like the Superbowl of conferences,” said Attila Hajdu, Chief Business Development Officer at Sirona Biochem. “It’s another important step in continuing our discussions with the types of companies that have the ability to commercialize our innovative compounds.”
About BIO International Convention
BIO International is the world’s largest, most influential biotech meeting. The convention regularly attracts the most powerful biotech and pharma players from 65 countries, offering powerful business partnering, networking and education that go far beyond professional development.
- Face-to-face partnering meetings with thousands of companies
- Company presentations from the industry’s up-and-coming innovators
- World-renowned speakers leading Keynote Luncheons and Super Sessions
- Session tracks covering timely issues in R&D, IP, Business Development, Commercialization, Digital Health, Personalized Medicine and more
- 1,700+ exhibitors offering a competitive edge in all fields
- Exciting networking and social events
For more information about the convention, visit convention.bio.org.
Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.